Saudi healthtech Aumet raises $12 million Series A to scale AI-driven procurement platform
Saudi Arabia-based healthtech startup Aumet has secured $12 million in Series A funding, led by Emkan Capital, marking a significant boost for its AI-driven procurement platform in the healthcare sector. The round, as reported by Wamda, also drew participation from Qatar Development Bank (QDB), SABAH VC, AAIC, and existing investors Shorooq Partners and Right Side Capital Management. This investment underscores growing investor confidence in regional tech innovations amid expanding digital health demands.
Founded in 2016 by Yahya Aqel, Adel Haddad, and Shahed Jaber, Aumet has established its headquarters in Saudi Arabia and specializes in an AI-first procurement operating system tailored for healthcare providers and pharmacies. The platform streamlines supply chain processes, enabling efficient sourcing of medical supplies and pharmaceuticals through intelligent automation. According to details from Wamda, the funding will primarily fuel advancements in Aumet's AI capabilities, enhancing operational efficiency for its clients.
Regional reports, including coverage from ZTO.sa, highlight additional participants such as Sakkala Group and Al-Salehiya Commercial Company, broadening the investor base across the Middle East and beyond. This diverse coalition reflects the cross-border appeal of Aumet's technology, particularly as Gulf nations prioritize healthcare digitization under initiatives like Saudi Arabia's Vision 2030.
The infusion of capital comes at a pivotal time for the MENA healthtech landscape, where procurement inefficiencies have long challenged providers amid rising demand. Aumet's solution addresses these pain points by reducing costs and improving inventory management, directly benefiting hospitals, clinics, and pharmacies. Stakeholders, including new backers like Emkan Capital, anticipate accelerated product development and market expansion.
Looking ahead, the company plans to leverage the funds for scaling its AI infrastructure and potentially entering new markets. While specific timelines remain undisclosed, this Series A positions Aumet to compete more aggressively in a sector projected to grow rapidly, driven by post-pandemic emphases on resilient supply chains and tech-enabled care delivery.